Treatment of colon cancer cells with 5-fluorouracil can improve the effectiveness of RNA-transfected antitumor dendritic cell vaccine by De Almeida, C. V. et al.
ONCOLOGY REPORTS  38:  561-568,  2017
Abstract. Non-cytotoxic concentrations of selected chemo-
therapeutic agents amplify the antigen presentation capacity of 
dendritic cells (DCs) and are able to increase the immunoge-
nicity of the colon cancer cell lineage HCT-116, as previously 
demonstrated by our group. Since this functional alteration 
was associated with changes in gene expression, we aimed to 
evaluate whether transcriptional changes of tumor cells can be 
transferred to DCs, increasing their ability to induce a specific 
antitumor response. Therefore, HCT-116 cells were treated 
with two different concentrations of 5-fluorouracil (5-FU), and 
their total RNA was transfected into human monocyte-derived 
DC, which function was evaluated through their ability to 
stimulate the proliferation of normal allogeneic T lymphocytes 
(MLR), and to generate cytolytic T cells. The transfected DCs 
demonstrated an increased percentage of CD83+, HLA-DR+, 
CD80+ and CD86+ cells. These phenotypical changes were 
followed by functional improvement demonstrated by the 
increased capacity of these DC to induce allogeneic T cell 
proliferation and to generate specific anti-HCT-116 cytolytic 
T cells, as demonstrated by IFN-γ production following in vitro 
challenge with tumor cells. Our results allow us to conclude 
that treatment of tumor cells with a non-toxic concentration 
of 5-FU induces immunogenic changes that are transferred to 
DC by transfection of total RNA.
Introduction
Primary treatment for colorectal cancer (CRC) is the surgical 
tumor resection, usually followed by adjuvant therapy with 
chemotherapeutic agents (1). In some cases local irradiation is 
associated with chemotherapy as a preoperative treatment (2). 
Chemotherapy is also the main treatment for that patients with 
metastatic diseases, with the fluoropyrimidine 5-fluorouracil, 
the hypomethylating agent 5-azacytidine, and the antimicrotu-
bule taxans such as paclitaxel and docetaxel, as the first line 
antineoplastic agents for CRC patients (3).
While surgery and radiotherapy are relatively precise and 
used to achieve local control, the cytotoxic chemotherapies 
show a systemic effect, which is usually followed by collateral 
damage to normal tissues. Indeed, conventional chemotherapy 
is based on administration of the maximum tolerated dose 
(MTD), which is the highest dose of a medication that induces 
tolerable side effects. This schedule induces cell cycle arrest 
and apoptosis not only in tumor cells, but also in non-malignant 
cells, including those of the immune system. Then, collateral 
damage include both myelosuppression and impaired func-
tion of dendritic cells (DCs) and lymphocytes (4). In contrast, 
the metronomic or dose-dense chemotherapy works with 
the administration of 10-33% of the conventional MTD in a 
shorter space of time between applications (daily or weekly). 
This schedule induces weaker adverse effects, promotes anti-
angiogenic effects (5,6), and activates dendritic cells while 
decreasing the activation of Treg cells (7-9).
In addition, our group has previously observed an immuno-
modulatory effect when chemotherapeutics are used in ultralow 
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non-toxic concentration (10,11). Such immunomodulation 
includes upregulation of mature DC markers, enhanced ability 
to stimulate allogeneic cells (10,12), and increased synthesis of 
IL-1β and IL-12 (11). It was also observed that ultralow concen-
tration of paclitaxel regulates the differentiation of murine 
conventional DCs into regulatory DCs (13), as well as prevents 
the generation of tolerogenic DCs (14). We also observed that 
treatment of HCT-116 tumor cells with low-concentrations of 
paclitaxel, is able to induce transcriptional changes of genes 
involved in their immunogenicity. These changes include 
increased expression of some genes associated with antigen 
presentation and tumor immunogenicity such as calmodulin, 
proteasomes, heat-shock proteins and cancer antigens (12). 
These changes in tumor immunogenicity affected the DC 
function as can be observed when tumor lysates are loading 
to them and improves their ability to induce the generation of 
anti-HCT-116 cytotoxic T cells (12).
Previous reports have shown that DCs can be primed by 
transferring both total tumor RNA (15) and mRNA (16,17), 
and we hypothesize that changes in the expression of these 
genes can be transferred to immature DCs by RNA transfec-
tion, thereby inducing them to synthesize tumor proteins or 
peptides. Since DCs are able to present peptides associated with 
both class I and II molecules, the transfection may improve the 
presentation of tumor antigens, generating specific cytotoxic 
T cell clones. In this study we tested the chemomodulatory 
effect of 5-fluorouracil (5-FU), one of the most used drug 
for treating CRC patients. There are no studies reporting the 
effects of low concentrations of 5-FU on tumor cells. Then, 
HCT-116 colorectal adenocarcinoma cells were pretreated 
with low concentrations of 5-FU, and their total rNA was 
transfected into monocyte-derived immature DCs to sensitize 
them for tumor antigens.
Our results show that transfection of DCs with total 
tumor RNA improved their ability to stimulate the prolif-
eration of allogeneic T cells, and enhanced the generation of 
autologous cytotoxic T cells. Generation of tumor-specific 
IFN-γ-producing cells was also increased when T cells were 
co-cultured with RNA-transfected DCs. These results lead us 
to conclude that transcriptional changes induced in tumor cells 
by low concentration of 5-FU can be transferred to DCs by 
rNA transfection, loading them to trigger a specific immune 
response, reinforcing the idea that simultaneous use of chemo-
therapy and immunotherapy can be an effective anti-CRC 
treatment.
Materials and methods
Tumor cell lines and cultures. Human colon cancer cells 
HCT-116, were cultured in RMPI-1640 medium (Cultilab, 
Brazil), supplemented with 10% FBs, 2 mm l-glutamine, 
1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 
10 mM HEPES and 0.1 mg/ml gentamicin (complete culture 
medium) at 37˚C under 5% Co2 tension. After 24 h of culture, 
cells were treated with the minimum effective (MEC = 
20 µM) or non-cytotoxic (NTC= 1 µM) concentrations of 
5-fluorouracil (5-FU) (eurofarma, são Paulo, Brazil) for 48 h, 
as previously determined by MTT-based cytotoxicity assay. 
Briefly, 2x103 cells were distributed on 96 flat-bottomed well 
culture plates and incubated with variable concentrations of 
5-FU (ranging from 0.06 to 100 µm). meC refers to the lowest 
drug concentration able to stop the tumor cell growth, while 
NTC refers to a concentration that does not affect cell growth 
(Fig. 1).
Institutional Ethics Committee Statement. All the proce-
dures involving cells of healthy donors were done according 
to the Declaration of Helsinki and approved by the local 
Ethics Committee at the School of Medicine of Botucatu 
(proc.043/2010-CEP).
Tumor cell RNA. Drug-treated tumor cells were washed with 
PBS, and their total RNA was immediately extracted using 
rNeasy mini kit (Qiagen, valencia, CA, UsA). rNA purity and 
concentration were checked by spectrophotometry 260/280 nm 
(Nanodrop Technologies, Inc., Wilmington, De, UsA). The 
rNA concentration was checked by Qubit (Thermo Fisher 
scientific Inc., Waltham, mA, UsA) and the quality was evalu-
ated by Bioanalyzer 2100 (Agilent Technologies, Santa Clara, 
CA, UsA). rNA integrity was confirmed by cDNA transcrip-
tion of the epCAm gene (Fig. 2).
Human monocyte-derived dendritic cells. DCs were 
differentiated from peripheral blood adherent mononuclear 
cells (PBMC) of healthy donors. PBMC were obtained by 
centrifugation on Ficoll-Isopaque gradient, suspended in 
AIm-v culture medium (Invitrogen, Carlsbad, CA, UsA) and 
seeded in 6-well culture plates (5x106/ml). After 1 h at 37˚C, 
non-adherent cells were removed and adherent monocytes 
were cultured in complete culture medium with 80 ng/ml 
recombinant human Gm-CsF and Il-4 (PeproTech, rocky 
Hill, NJ, UsA) for 6 days (18), when they were transfected 
with total tumor RNA and kept in culture for additional 24 h. 
Immature DCs were submitted to four culture conditions: DCs 
(non-transfected immature DCs); WT (DCs transfected with 
rNA of untreated tumor cells); meC (DCs transfected with 
rNA of tumor cells pretreated with 20 µm of 5-FU), and NTC 
(DCs transfected with RNA of tumor cells pretreated with 
1 µm 5-FU). All the procedures involving cells of healthy 
donors were done according to the Declaration of Helsinki 
and approved by the local Ethics Committee at the School of 
Medicine of Botucatu (proc.043/2010-CEP).
DC transfection with tumor total RNA. Immature DCs were 
seeded in 6-well plates (2x105 cell/well) with antibiotic-free 
and serum-free fresh RPMI-1640 medium, and cultured for 
18 h at 37˚C. Then, cells were transfected with 5 µg of total 
RNA of tumor cells submitted to the above mentioned treat-
ments, using 7 µl of DMRIE-C reagent (Invitrogen), following 
the manufacturer's instructions. Transfected cells were main-
tained in culture for 24 h and harvested for subsequent assays.
Expression of epithelial cell adhesion molecule (EpCAM) 
by transfected cells. In order to confirm the effectiveness 
of transcription, total RNA was extracted from transfected 
DC, and cDNA was synthesized using SuperScript III 
Reverse Transcriptase (Invitrogen), following the manufac-
turer's instructions. Transfection of tumor RNA into DCs 
was evidenced by neo-expression or increased expression of 
epCAm gene by rT-PCr using GoTaq Green mix Promega, 
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and EpCAM specific primers (sense: ATCGTCAATGCC 
AGTGTACTTCA and antisense: TTTGCTCTTCTCCCA 
AGTTTTGAG). Electrophoresis of RT-PCR products was 
performed in agarose gel 0.8%.
DC phenotyping. For the phenotype analysis, both transfected 
and control DCs were incubated with mAbs for 30 min and 
washed with PBS containing 0.1% bovine serum albumin 
(BSA) and 0.1% sodium azide. DCs were labeled with 
mAbs for MHC-Class II-PE, CD11c-APC, CD83-PE-Cy7, 
CD80-APC-H7 and CD86-FITC (BD Pharmingen, san Jose, 
CA, UsA). samples were read in a FACsCanto II cytometer 
(Becton-Dickinson, san Jose, CA, UsA) and analyzed by the 
software FlowJo, version 7.2.4.
Mixed leukocyte reaction (MLR). Functional activity of 
transfected DCs was first evaluated through their ability to 
stimulate the proliferation of normal allogeneic T lympho-
cytes. Transfected DCs from all different donors were 
co-cultured with T lymphocytes from the same healthy donor 
in flat-bottomed 96-well plates in different DCs: T proportions 
(1:1, 1:3, 1:10 and 1:30). The lymphocyte proliferation was 
evaluated 4 days later based on the ability of living cells to 
transform MTT into formazan crystals, which were further 
solubilized with dimethylsulphoxide (DMSO) and measured 
by spectrophotometry at 540 nm. Results were expressed as 
proliferation index, calculated by the equation [(experimental 
OD - lymphocytes OD)/lymphocytes OD], where lymphocytes 
OD refers to the formazan reduction by only lymphocyte 
suspension, whereas experimental OD refers to the measure-
ment of lymphocytes cultured with DCs.
Generation of cytolytic T lymphocytes and antitumor 
cytotoxicity assay. For the generation of specific antitumor 
T cells, transfected DCs were co-cultured with autologous 
T lymphocyte-rich suspension in complete culture medium 
supplemented with Il-7 (5 ng/ml) and Il-2 (40 IU/ml). The 
culture was pulsed with IL-2 every three days for 14 days. On 
day 14, the lymphocytes were harvested, and evaluated for 
cytotoxic activity against HCT-116 target cells.
Lymphocytotoxicity assay was performed with HCT-116 
cells, previously cultured in a flat-bottomed 96-well plate, 
and dyed with MTT solution. In vitro generated lymphocytes 
were put on HCT-116 monolayers (5:1/Ly:HCT-116), and then 
co-cultured for 18 h at 37˚C under 5% Co2. Next, wells were 
carefully washed in order to remove suspended lymphocytes 
and dead cell debris. The percentage of surviving target cells 
was estimated by measuring the optical density of residual 
formazan crystals dissolved in DMSO.
IFN-γ and IL-10 detection. Supernatants of the lymphocytes 
co-cultured with tumor cells were collected at the final 
lymphocyte toxicity assay and preserved at -80˚C for further 
analysis of in vitro synthesis of IFN-γ and IL-10 by ELISA, 
according to the manufacturer's instructions (R&D Systems, 
minneapolis, mN, UsA).
Statistical analysis. Homogeneity of variance was accessed 
by the Bartlett test (19), and data were analyzed by analysis 
of variance (ANOVA) followed by the Tukey-Kramer test for 
multiple comparisons. Differences were considered significant 
when the error probability was <5% (p<0.05).
Results
Transfected DCs show higher levels of EpCAM expression. 
Epithelial cell adhesion molecule (EpCAM) is a transmem-
brane protein with dual function: cell adhesion and mitogenic 
signaling. It is normally expressed in the basal membrane 
layers and is overexpressed in various carcinomas and tumor-
initiating cells (i.e., cancer stem cells) (20). Fig. 2 illustrates 
the constitutive expression of EpCAM gene in HCT-116 cells, 
and the increased expression in all RNA-transfected DC, 
whereas non-transfected control cells show a very light or 
absent expression. Since EpCAM can also be expressed by 
normal cells, we considered it the housekeeping gene. The 
Figure 1. Determination of minimum effective (meC) and non-toxic (NTC) 
concentrations of 5-FU on HCT-116 cell line. The cell monolayer was treated 
for 48 h with increasing concentrations of 5-FU (from 0.06 to 100 µm), and 
viable cells were estimated by MTT assay. Twenty micromoles was the lowest 
concentration able to keep the number of cells in a similar amount of those 
originally put in the culture (basal control) and was defined as meC, while 
1 µM was the non-toxic concentration (NTC). Mean and standard deviation 
of four independent assays. Negative control corresponds to spontaneous cell 
growth for 48 h; basal control corresponds to cells cultured for 24 h repre-
senting the original number of cells put in culture. (a≠b; p<0.0001, ANovA, 
followed by Tukey test).
Figure 2. rT-PCr electrophoresis shows increased expression of epCAm 
gene after transfection with total RNA of tumor cells treated with different 
doses of 5-FU. electrophoresis of cDNA prepared with: 1, rNA of wild-type 
HCT-116; 2, rNA of non-transfected DCs; 3, DCs transfected with rNA of 
wild-type HCT-116; 4, DCs transfected with rNA of HCT-116 pretreated 
with meC; 5, DCs transfected with rNA of HCT-116 pretreated with NTC. 
Representative results of 6 independent assays.
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transfection process was not able to increase its expression 
(data not shown).
Effect of transfection on DC differentiation and maturation. 
The next step was to analyse the influence of the transfection 
on the expression of DC differentiation and maturation markers 
by flow cytometry. Fig. 3 shows that transfection of these cells 
with tumor rNA increased the frequency of CD83+, HLA-DR+, 
CD80+ and CD86+ (N=6). Transfection with RNA of untreated 
(wild-type) HCT-116 cells was enough to slightly increase the 
percentage of cells expressing these markers, as observed for 
CD86 (Fig. 3D). However, only those DCs transfected with 
rNA of tumor cells pre-treated with 5-FU, showed signifi-
cantly higher number of cells expressing HLA-DR, CD83 and 
CD80. In addition, analysis of medium fluorescence intensity 
(mFI) showed increased expression of CD86 molecules in cells 
transfected with RNA of HCT-116 cells treated with both NTC 
and meC of 5-FU (DC = 991.8±224.0; WT = 1,511.0±446.6; 
Cem = 2,627.8±351.7; NTC = 2,504.2±695.6; Fig. 4).
DC transfection with RNA of 5-FU-treated tumor cells 
increases allogeneic antigen presentation. In order to analyse 
the effect of transfection on the antigen-presentation func-
tion of DCs, we performed the mlr assay. Fig. 5 shows that 
RNA-transfected DCs induce higher levels of lymphocyte 
proliferation than non-transfected cells (group DCs). Previous 
exposure of tumor cells to low concentrations of 5-FU 
increased the effect of RNA-transfected on DC function, in 
comparison with cells transfected with tumor cell wild-type 
rNA (DCs  = 4.01±0.62; WT = 5.74±0.91; meC = 8.21±0.95; 
NCT = 8.86±1.13; expressed as stimulation index); mean ± 
standard deviation of 6 independent assays.
DC transfection with tumor RNA enhances the in vitro genera-
tion of CTL. Cell death mediated by cytotoxic T lymphocytes 
is considered the main mechanism for killing MHC class I+ 
target cells. Thus, we tested the efficiency of transfected DCs 
for generating autologous tumor specific T cells. We observed 
that the lymphocyte cultured with RNA-transfected DCs 
yielded anti-HCT-116 cytotoxic cells with higher activity than 
those cultured with control DCs. The results in Fig. 6 show 
that DCs transfected with rNA of 5-FU-treated tumor cells 
(both MEC and NTC) are able to induce higher levels of anti-
HCT-116 than both DCs and WT controls (DC = 15.87±10.31; 
WT = 30.81±9.711; meC = 37.60±9.17; NCT = 47.64±9.92; 
expressed as percentage of specific lysis; N=6).
Figure 3. Tumor rNA transfection increases the frequency of DCs with maturation/activation phenotype. monocytes of healthy donor were differentiated 
into dendritic cells by treatement with Gm-CsF and Il-4 for 6 days. Then, these immature DC were transfected with rNA of tumor cells under different 
culture conditions, and phenotype was analyzed 24 h later. Data of DCs from 6 healthy donors were acquired by flow cytometry in two independent assays. 
DC, non-transfected dendritic cells; WT, DC transfected with rNA from wild-type HCT-116; meC, DC transfected with rNA of HCT-116 treated with 
minimum effective concentration (20 µm); NTC, DC transfected with rNA of HCT-116 treated with non-toxic concentration (1 µm). statistical analysis by 
ANOVA and Tukey-Kramer multiple comparison test: *p≤0.05; **p≤0.01; ***p≤0.001.
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In vitro cytokine synthesis. IFN-γ is one of the main cytokines 
involved in the generation of an effective antitumor immune 
response. since IFN-γ is produced by both Th1 (T helper 1) 
and activated CTLs, its evaluation in the CTL-assay superna-
tant is a strong tool for inferring specific responses. Fig. 7A 
shows that T cells generated by co-cultures with transfected 
DCs produce higher IFN-γ levels than the control DCs 
(DCs = 103.3±6.4; WT = 122.7±12.00; meC = 129.5±9.0; 
NCT = 133.1±9.1 pg/ml), however, the DC transfection did not 
change the ability of these cells to induce IL-10 production 
(Fig. 7B). No differences were observed between meC, NTC 
and WT. In order to evaluate the relative effect on the Th1/Th2 
responsiveness profile, we calculated the IFN-γ/Il-10 ratio, 
and Fig. 7C shows that transfection of rNA from drug-treated 
tumor cells (MEC and NTC groups) increased this param-
eter in comparison with the DC group (DCs = 3.21±0.19; 
WT = 3.75±0.39; meC = 4.17±0.24; NCT = 4.06±0.37).
Discussion
The anti-metabolic agent 5-fluorouracil acts by interfering 
with DNA and RNA synthesis in both normal and tumor 
Figure 4. DCs transfected with 5-FU-treated tumor rNA increases the expression of CD86 molecules on CD11+DCs. Representative data of CD86 expressed on 
control (A) and transfected DCs (B-D). Left side histograms (grey) show the intensity of isotypic control and the right side peaks represent the CD86 expression. 
(E) Mean and standard deviation of 6 samples analyzed in two independent experiments. Statistical analysis by ANOVA and Tukey-Kramer multiple comparison 
test; ***p≤0.01.
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cells (21). Its metabolite f luorouridine triphosphate is 
extensively incorporated into RNA, disrupting the normal 
processing and function of cells (22,23). This led us to evaluate 
whether rNA changes induced by 5-FU can be transferred to 
monocyte-derived DCs, enhancing their feasibility for use as a 
therapeutic anti-CRC vaccine.
First, we chose the best strategy for rNA transfection into 
DCs, comparing electroporation and liposomal approaches. 
Since electroporation was very aggressive toward DCs and 
induced a high level of cell mortality (data not shown), we tested 
different liposome reagents, and achieved the best results with 
DMRIE-C reagent (Invitrogen). In order to show the ability of 
DMRIE-C to transfect total tumor RNA into DCs, we performed 
rT-PCr assay using the specific primer for the epithelial cell 
adhesion molecule (EpCAM) gene. EpCAM is a carcinoma-
associated antigen, expressed in gastrointestinal carcinomas 
and most normal epithelial cells (20). Although some donors we 
analyzed have this gene constitutively expressed (EpCAM+), its 
expression increased following tumor RNA transfection, while 
EpCAM-samples showed de novo expression of this gene. This 
observation is in agreement with previous reports that EpCAM 
is constitutively expressed on normal cells of healthy individuals 
and absent in others (24), being overexpressed in tumor cells.
In order to investigate the capacity of RNA-transfected 
DCs to activate T lymphocytes we first analyzed their ability 
to induce T cell alloreactivity by performing the MLR assay. 
Our data show that tumor RNA is effective in stimulating DC 
function, since transfected DCs more efficiently promoted 
proliferation of allogeneic T lymphocytes than non-trans-
fected cells. Furthermore, transfection of 5-FU-treated tumor 
rNA (meC and NTC) showed a higher efficiency than rNA 
of untreated tumor cells (WT) to modulate these functions. 
These results are in agreement with the increase percentage 
of HLA-DR+, CD83+, CD80+ and CD86+ cells among DCs, 
transfected with RNA from NTC-treated or MEC-treated 
tumor cells, since these molecules are markers of DC matu-
ration/activation and are able to enhance the formation of 
immune synapses with TCR (25). This view is reinforced by 
the increased expression of co-stimulatory molecule CD86 by 
DCs, transfected with rNA of 5-FU-treated cells.
These results instigated us to analyze whether the proposed 
DC-loading approach would improve their ability to induce 
CTL generation. We observed that the DCs loaded with RNA 
of cells exposed to non-toxic concentration of 5-FU was much 
more efficient than not transfected control or those transfected 
with wild-type tumor RNA. Therefore, our results reinforce 
the view that low 5-FU concentrations are able to promote 
changes in tumor-cell gene expression (12), which can be 
transferred to normal DCs by RNA transfection. Such results 
are in agreement with previous reports that RNA-transfected 
DCs can stimulate tumor antigen-specific CTls in different 
cancer systems, such as prostate (16), cervical (26), renal (27), 
and colon (28) cancers.
Another usual parameter to verify the generation of 
specific antitumor response is the in vitro production of 
IFN-γ by T cells, following a challenge with specific targets. 
Our results show that autologous T lymphocytes generated 
during the co-culture with DCs of both MEC and NTC groups 
showed increased IFN-γ production, in agreement with the 
findings on the cytotoxic activity of these lymphocytes. since 
no changes were observed on IL-10 production, we calculated 
the IFN-γ:IL-10 ratio, and the data indicate that RNA transfec-
tion is able to drive cytokine responsiveness to the Th1 profile, 
thus enhancing the establishment of an antitumor status, as we 
demonstrated in gastrointestinal cancers (29). Since stimula-
tion of MHC-I and -II expression is one of the main roles of 
IFN-γ, increased HlA-Dr expression observed in this study 
is also in accordance with the data on the production of such 
a cytokine. IFN-γ facilitates the interaction between DCs and 
tumor target cells, and potentiates the stimulatory effect of 
DCs on the immune system. In a parallel study developed by 
Figure 5. DC transfection with tumor rNA enhances the in vitro allogeneic 
response by T-cells. DCs were transfected with tumor RNA and co-cultured 
with allogeneic lymphocytes for 5 days, in order to analyze the capacity of 
transfected DCs to activate T lymphocytes (Ly). Assays were done culturing 
DC from 6 different donors with T lymphocytes (responder cells) from the 
same donor, and cell proliferation index was calculated based on incorpora-
tion of MTT by living cells. The DCs:Ly ratio of 1:10 is illustrated. Mean and 
standard deviation using DC were prepared as follows: DC, non-transfected 
dendritic cells; WT, DC transfected with rNA from wild-type HCT-116; 
MEC, DC transfected with RNA of HCT-116 treated with minimum effective 
concentration (20 µm); NTC, DC transfected with rNA of HCT-116 treated 
with non-toxic concentration (1 µM). Statistical analysis by ANOVA and 
Tukey-Kramer multiple comparison test: *p≤0.05.
Figure 6. In vitro generation of cytotoxic T cells (CTL) is improved by trans-
fection of DCs with rNA of 5-FU treated tumor cells. specific antitumor 
cytotoxicity of CTL generated in vitro culturing RNA-transfected DCs with 
autologous T lymphocytes for 14 days. For the cytotoxicity test, CTl were 
added on an MTT-labeled HCT-116 cell monolayer and incubated for 18 h 
using a 50:1 effector:target ratio. Percentage of specific lysis was calculated 
comparing the optical density of living cells (containing formazan crystals). 
Mean and standard deviation of 6 independent assays with different DC 
donors. DC, non-transfected dendritic cells; WT, DC transfected with rNA 
from wild-type HCT-116; meC, DC transfected with rNA of HCT-116 
treated with minimum effective concentration (20 µm); NTC, DC transfected 
with RNA of HCT-116 treated with non-toxic concentration (1 µM). Statistical 
analysis by ANOVA and Tukey-Kramer multiple comparison test: *p≤0.05.
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our group, we observed that treatment of a colorectal tumor cell 
line with low concentrations of paclitaxel induced the expres-
sion of HSP40, HSP70 and HSP90, whereas DCs loaded with 
lysates from such cells also showed increased ability to induce 
allogeneic lymphoproliferative response (unpublished data). 
It is possible that tumor exposure to 5-FU also increases the 
expression of these proteins. If so, HSPs on target cells could 
preferentially bind to TLR-expressing DCs, increasing the 
antigen uptake by immature DCs. This view is reinforced by 
the recent observation that murine colon cancer cells (CT-26) 
in vitro treated with 5-FU and/or oxaliplatin induces secretion 
of HSP70 and the high-mobility group box-1 (HMGB1) (29), 
that seem to be responsible for the upregulation of DC acti-
vation markers (HLA-DR, CD80 and CD86), via interaction 
with TLR4. In addition, putative expression of HSPs by tumor 
cells (30) could work as target for CTL (31) and NK cells (32).
Taken together, the obtained results corroborate our previous 
observation that exposure of tumor cells to low concentrations 
of cytotoxic agents increases their immunogenicity (12), rein-
forcing our hypothesis that changes induced by this treatment 
can be successfully transferred to DCs by transfection of total 
tumor RNA, priming them to trigger a specific antitumor 
response. Besides the number of different protocols proposed 
to prime DCs, the best way to prepare antitumor therapeutic 
DC-based vaccine is still unclear (33), leading us to conclude 
that our protocol deserves a wider investigation in order to be 
improved for clinical application, especially to reinforce the 
feasibility of administration of low doses of chemotherapeutic 
agents in combination with therapeutic DC vaccines. In conclu-
sion these data support and reinforce the idea that simultaneous 
use of chemotherapy and immunotherapy can be an effective 
anti-CRC treatment.
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